ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

NextKidney B.V. raises 6M EUR for realization of a portable sorbent based hemodialysis device

Realization of the first truly portable - plug and play – user friendly home hemodialysis device "Neokidney"

LAUSANNE, VAUD, ZWITSERLAND, July 2, 2021 /EINPresswire.com/ -- Amsterdam (NL), Lausanne (CH) and Singapore, June 21, 2021. NextKidney BV –announced today that they raised 6M EUR in the first funding round. Herewith the next step is taken in the realization of the first truly portable - plug and play – user friendly home hemodialysis device that, contrary to other Home dialysis equipment currently available or under development, only uses 4 liters of fluids and can be used anywhere. This funding round enables NextKidney BV to make the prototype ready for clinical trials. Funds were raised by a French syndicate - led by Jerome Augustin - and founders Debiotech SA and Dutch Kidney Foundation.

The treatment of kidney failure is a growing issue in public health policies. It is one of the main sources of healthcare costs in our western societies with over $35 Bio spent in 2018 only in the United States, while there is an annual growth of 6% of kidney patients dependent on dialysis worldwide. Jérôme Augustin, Chief Executive Officer of NextKidney BV: “The Dialysis market will even grow more in the years to come asking for a device that enables patients to perform their dialysis treatment any place at any time, not hampered by logistics of fluids or infrastructure, enabling patients to longer stay connected to social and professional lives”.

Prototype ready for clinical trials
This funding round enables NextKidney BV, the recently founded Dutch parent company of NextKidney SA at Lausanne, to make the prototype ready for clinical trials. “Currently we discuss with interested parties to fund NextKidney through its clinical trials next year and market introduction early 2023”, according to John Stooker, Chief Financial Officer at NextKidney BV.

A shift to homecare
A shift from hospital to homecare is strongly advocated by patients, desiring not only more individualized medical treatment but also seeking to significantly improve their quality of life. Consequences of COVID-19, making home treatment an imperative for many, underline the urgency of this shift. Currently available Home HD products require a significant amount of fluid (over 20L) for each treatment, either delivered at home with considerable logistical problems or generated through a bulky and non-transportable equipment. Thanks to an innovative single-use sorbent cartridge, only 4L of fluids will be needed for each session, making NeoKidney® a true revolution in the Home Dialysis landscape.

Tom Oostrom, managing director of the Dutch Kidney Foundation and member of the Supervisory Board of NextKidney BV, sees the development of the portable hemodialysis cycler as a paradigm change. “Dialysis patients deserve to gain back control over their lives and in parallel society needs to see reduced pressure on worldwide health care systems ”.

It is in this context NextKidney B.V. and its partners -Debiotech SA, Dialyss Pte Ltd and a collective of the Dutch Kidney Foundation and three major Dutch health care insurers - have been working over the last seven years on the NeoKidney® with the mission of radically changing home hemodialysis by offering a really small, portable and easy to use solution, giving the patient back some of his or her freedom.

Frederic Neftel, MD, President of Debiotech SA and member of the Supervisory Board of NextKidney BV,, comments on this important step for the company: “This first financial round is an essential driving force to bring a breakthrough alternative into the hands of patients in the best possible time. Thanks to a great team of experts, led by Jérôme Augustin, we have a great confidence in the future of Nextkidney and the Neokidney Product which will be the first one to really simplify the entire logistics at the patient’s home to make it more cost effective and available in all circumstances”.

About NextKidney B.V.
NextKidney’s mission is to develop and commercialize the NeoKidney® home hemodialysis device, the real breakthrough in home hemodialysis. Placing the patient and his quality of life at the center of its approach, the company uses innovative technologies to offer a safe, practical and easy-to-use solution as quickly as and widely as possible throughout the world.

More information about NextKidney B.V. and the NeoKidney® can be found at www.nextkidney.com.

John Stooker
NextKidney BV
+31 6 55355105
j.stooker@nextkidney.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.